A valid prescription requires a telehealth consultation with a prescriber. No medication is dispensed without clinical evaluation.
These compounded medications are not FDA-approved and have not undergone FDA review for safety or efficacy. Quality and purity depend on pharmacy practices.
Tirzepatide
Dual GLP-1 / GIP Incretin Agonist
Compound Specifications
Tirzepatide
Dual GLP-1 / GIP Incretin Agonist
Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor co-agonist. In clinical trials, simultaneous activation of both incretin pathways demonstrated body weight reduction and improvements in glycemic and metabolic markers.
Simultaneously engages GIP and GLP-1 receptors, enhancing pancreatic beta-cell sensitivity, supporting adipose lipid metabolism, and minimizing nausea often seen with single-pathway agonists.
Prescriber Oversight: All prescriptions are issued only after evaluation by a licensed prescriber determines treatment is appropriate. Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Important Safety Information
Important Safety Information: Tirzepatide therapy requires individualized medical evaluation. Treatment may not be appropriate for every patient. A licensed medical provider will review medical history, current medications, contraindications, potential adverse effects, and other clinical factors before prescribing. Patients should report new or worsening symptoms promptly and seek emergency care for severe or life-threatening symptoms.
Report suspected adverse reactions to your provider and to FDA MedWatch at 1-800-FDA-1088 or fda.gov/medwatch.
Clinical Evidence for Tirzepatide
Clinical outcomes described in published studies generally relate to FDA-approved tirzepatide products studied under specific protocols. The compounded tirzepatide formulation offered through this platform is not FDA-approved and has not been reviewed by FDA for safety, effectiveness, or manufacturing quality.
Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Individual results may vary. Clinical outcomes reported in studies may not predict an individual patient's response, and compounded formulations are not FDA-approved.
Administered once weekly subcutaneously, titrated under physician direction according to clinical response and tolerance.
Frequently Asked Clinical Questions
Why is Tirzepatide preferred over single GLP-1s?
The dual GIP/GLP-1 mechanism is studied in clinical trials for its effects on metabolic markers and body weight.
Where is Tirzepatide compounded?
All preparations are prepared and dispatched from licensed U.S. compounding pharmacies pursuant to a valid prescription.
Tirzepatide is a compounded preparation that is not FDA-approved and requires a prescription after evaluation by a licensed provider. Results vary, and therapy is not appropriate for everyone. This page is for informational purposes only and does not constitute medical advice. Consult a licensed clinician before starting any new therapy.
Compounded preparations are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing quality. This page is for informational purposes only and does not constitute medical advice.